Warp Drive Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Warp Drive Bio, Inc.
Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
Finance Watch: Billions Of Dollars In Offerings Despite US Biopharma Stock Slump
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
EQRx Aims To Upend Industry’s Pricing Model, With Me-Too Drugs
With a $200m series A financing and an illustrious founding team, including Alexis Borisy and Peter Bach, EQRx plans to develop cheap me-too drugs. The start-up could pose a new threat to big pharma.
Finance Watch: Among Multiple Mega-Rounds, Revolution Raises $100m For RAS Programs
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
- Drug Discovery Tools
Drug Discovery Tools
- Molecular Diversity
- Natural Products
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.